Neeraj Agarwal, MD: If we look at the prognosis of patients who have renal insufficiency, are not candidates for therapy with cisplatin, and have locally advanced or metastatic urothelial carcinoma, the median survival reported from past studies on patients treated with carboplatin-based chemotherapy has been around 10 to 12 months. In fact, it is inferior for those patients who are able to receive cisplatin-based chemotherapy.
Until now, we really were waiting for these patients to have disease progression after they had completed carboplatin-gemcitabine. They were essentially taking a treatment break, and then we were hoping for the best. Invariably, we see disease coming back in the form of localized recurrence or metastatic disease in most of these patients.
A multidisciplinary approach comes into play when these patients are presenting to us for the first time. For example, in this case where local regional lymphadenopathy is present, and this patient was deemed ineligible for radiation therapy or surgery, this is really a call by a multidisciplinary team. Surgeons, radiation oncologists, medical oncologists all have to chime in.
Of course, the patient’s wishes are paramount. Many patients do not want to have a cystectomy or may not want to have radiation therapy. Of course, those things are taken into account. But in collaboration with the patient, once we have determined that patient is not a candidate for definitive surgery or radiation, the option is systemic chemotherapy. Until now, systemic chemotherapy alone was the definitive answer for these patients. For example, start with cisplatin-based chemotherapy or carboplatin-based chemotherapy and then hope for the best.
Transcript edited for clarity.
Case Overview: A 73-Year-Old Male With Urothelial Carcinoma
Initial presentation
Clinical workup
Treatment
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Immunotherapy Meets the Frontline in Bladder Cancer, Leaving Gaps in Later Lines
June 24th 2024Recent data, trials, approvals, and presentations during the 2024 American Urological Association Annual Meeting paint a positive treatment landscape for patients with metastatic and non–muscle-invasive bladder cancer.
Read More
High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro
June 5th 2024A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.
Read More